A Paediatric Phase I/II Study Of Intermittent Dosing Of The Mek-1 Inhibitor Selumetinib In Children With Neurofibromatosis Type-1 And Inoperable Plexiform Neurofibroma And/Or Progressive Optic Pathway Glioma

Trial Profile

A Paediatric Phase I/II Study Of Intermittent Dosing Of The Mek-1 Inhibitor Selumetinib In Children With Neurofibromatosis Type-1 And Inoperable Plexiform Neurofibroma And/Or Progressive Optic Pathway Glioma

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Selumetinib (Primary)
  • Indications Glioma; Neurofibromatoses
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms INSPECT
  • Most Recent Events

    • 02 Nov 2017 New trial record
    • 01 Nov 2017 Planned primary completion date changed from 1 Jun 2019 to 1 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top